Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of QX005N in adults with prurigo nodularis
ChiCTR2400082720Phase 3Not yet recruiting
- Sponsor
- Zhang Jianzhong
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of QX005N in prurigo nodularis (PN) (3 arms), sponsored by Zhang Jianzhong. Primary endpoint: Percentage of participants with reduction in weekly average Worst-Itch Numeric Rating Scale by at least 4 points at week 16. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
QX005N
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on ChiCTR2400082720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082720.